一项关于艾司西酞普兰（来士普）治疗“阿尔茨海默病抑郁（dAD）”的开放标签研究。
An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD).
作者信息
Rao V, Spiro J R, Rosenberg P B, Lee H B, Rosenblatt A, Lyketsos C G
机构信息
Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry & Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
出版信息
Int J Geriatr Psychiatry. 2006 Mar;21(3):273-4. doi: 10.1002/gps.1459.
BACKGROUND
Depression is a frequent neuropsychiatric complication of Alzheimer's Disease.
METHODS
This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study.
CONCLUSION
Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.
背景
抑郁症是阿尔茨海默病常见的神经精神并发症。
方法
本研究在一项为期8周的开放标签治疗研究中，依据美国国立精神卫生研究所（NIMH）共识标准，调查了艾司西酞普兰（来士普）治疗阿尔茨海默病性抑郁症（dAD）的安全性和有效性。
结论
在本研究中，艾司西酞普兰治疗dAD有效且安全。有必要开展更大规模的对照研究，以进一步评估这种医疗脆弱人群中情绪和行为障碍的疗效。
Zotero 插件